Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Santhera Pharmaceuticals Holding AG (SPHDF)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
1.41000.0000 (0.00%)
At close: 02:28PM EST
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close1.4100
Open1.4100
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range1.4100 - 1.4100
52 Week Range1.3700 - 5.6100
Volume500
Avg. Volume892
Market Cap29.428M
Beta (5Y Monthly)1.16
PE Ratio (TTM)N/A
EPS (TTM)-3.3050
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
N/A

Subscribe to Yahoo Finance Plus to view Fair Value for SPHDF

Learn more
View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • SANTHERA PHARMACEUTICALS HOLDIN
    Daily – Vickers Top Insider Picks for 01/13/2022The Vickers Top Insider Picks is a daily report that utilizes a proprietary algorithm to identify 25 companies with compelling insider purchase histories based on transactions over the past three months.
    Rating
    Fair Value
    Economic Moat
    3 days agoArgus Research
View more
  • GlobeNewswire

    Santhera Enters into Exclusive License Agreement with Sperogenix for Vamorolone in Rare Diseases in the Greater China Region

    Ad hoc announcement pursuant to Art. 53 LR Sperogenix will receive exclusive rights for development and commercialization of vamorolone for the treatment of Duchenne muscular dystrophy (DMD) and any other rare diseaseSanthera to receive a double-digit upfront cash payment plus short-term US-regulatory milestones amounting to USD 20 million combined, in a deal valued at USD 124 millionSanthera continues to focus with own organization on bringing vamorolone to patients in US and Europe, with a rol

  • GlobeNewswire

    Santhera’s Shareholders Approve all Board Proposals at Today’s Extraordinary General Meeting

    Pratteln, Switzerland, December 15, 2021 – Santhera Pharmaceuticals (SIX: SANN) announces that its shareholders have approved all proposals by the Board of Directors at the Extraordinary General Meeting (EGM) held today at the Company’s domicile in Pratteln, Switzerland. In total, 15,454,014 shares equaling 28.3% of the Company’s share capital were represented. “We thank Santhera’s shareholders for their approval of all our motions,” said Elmar Schnee, Chairman of the Board of Directors. “Their

  • GlobeNewswire

    Santhera to Host Investor Conference Call — Looking Ahead to 2022

    Pratteln, Switzerland, December 6, 2021 – Santhera Pharmaceuticals (SIX: SANN) is pleased to invite investors, shareholders, media representatives and interested parties to join a conference call on December 8, 2021 at 15:00 CET. In a moderated session, senior executives from Santhera will reflect on recent developments and discuss upcoming milestones as well as expectations ahead of 2022. The interactive session will be moderated by Octavian’s Laura Pfeifer-Rossi, who has been working in the he

Advertisement
Advertisement